Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia

References

• World Health Organization. HIV Drug Resistance Report 2019. Geneva, Switzerland: World Health Organization; 2019. 2019 (WHO/CDS/ HIV/19.21). Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Gupta RK, Shafer RW, Ndembi N. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16(5):565–575. doi:10.1016/S1473-3099(15)00536-826831472
   PubMed Web of Science ®Google Scholar
• EFMH. National Guidelines for Comprehensive HIV Prevention, Care and Treatment. Addis Ababa, Ethiopia: Federal Ministry of Health(FMOH); 2014.
   Google Scholar
• EPHI. HIV Related Estimates and Projections for Ethiopia–2017. Addis Ababa, Ethiopia: Ethiopian Public Health Institute; 2017.
   Google Scholar
• Barnabas G, Sibhatu M, Berhane Y. Antiretroviral therapy program in Ethiopia benefits from virology treatment monitoring. Ethiop J Health Sci. 2017;27(1):1–2. doi:10.4314/ejhs.v27i1.1S
   PubMedGoogle Scholar
• Abdissa A, Yilma D, Fonager J, et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis. 2014;14:181. doi:10.1186/1471-2334-14-18124708645
   PubMed Web of Science ®Google Scholar
• Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014;14:28. doi:10.1186/1471-2334-14-2824422906
   PubMed Web of Science ®Google Scholar
• Mulu A, Maier M, Liebert UG. Low incidence of HIV-1C acquired drug resistance 10 years after roll-out of antiretroviral therapy in Ethiopia: a prospective cohort study. PLoS One. 2015;10(10):e0141318. doi:10.1371/journal.pone.014131826512902
   PubMed Web of Science ®Google Scholar
• Abegaz W. Genomic characterization of HIV-1 isolates from Ethiopian patients: baseline studies on antiretroviral drug resistance and sub-type variations. A Thesis Submitted to the school of Graduate Studies of the Addis Ababa University in Partial Fulfillment of the Requirement for the Degree of Doctor of Philosophy in Medical Microbiology, Addis Ababa, Ethiopia. 2011.
   Google Scholar
• Ssemwanga D, Lihana RW, Ugoji C, et al. Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Rev. 2015;17(1):3–20.25427100
   PubMed Web of Science ®Google Scholar
• Lo Presti A, Farcomeni S, Fontanelli Sulekova L, et al. Characterization of HIV-1 subtypes among south Sudanese patients. AIDS Res Hum Retroviruses. 2019;35(10):968–971. doi:10.1089/aid.2019.013331280584
   PubMed Web of Science ®Google Scholar
• Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular epidemiology of HIV-1 in African countries: a comprehensive overview. Pathogens. 2020;9(12):1072. doi:10.3390/pathogens9121072
   Web of Science ®Google Scholar
• Parikha UM, McCormicka K, Zylb GV, Mellorsa JW. Future technologies for monitoring HIV drug resistance and cure. Curr Opin HIV AIDS. 2017;12:182–189. doi:10.1097/COH.000000000000034428059958
   PubMed Web of Science ®Google Scholar
• Lapointe HR, Dong W, Lee GQ, et al. HIV drug resistance testing by high-multiplex “wide” sequencing on the miseq instrument. Antimicrob Agents Chemother. 2015;59(11):6824–6833. doi:10.1128/AAC.01490-1526282425
   PubMed Web of Science ®Google Scholar
• Simen B, Simons JF, Hullsiek K, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2009;199:693–701. doi:10.1086/59673619210162
   PubMed Web of Science ®Google Scholar
• Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One. 2010;5:e10952. doi:10.1371/journal.pone.001095220532178
   PubMed Web of Science ®Google Scholar
• Huber M, Metzner KJ, Geissberger FD, et al. MinVar: a rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. J Virol Methods. 2017;240:7–13. doi:10.1016/j.jviromet.2016.11.00827867045
   PubMed Web of Science ®Google Scholar
• Mohamed S, Penaranda G, Gonzalez D, et al. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure. AIDS. 2014;28(9):1315–1324. doi:10.1097/QAD.000000000000026724698843
   PubMed Web of Science ®Google Scholar
• Ode H, Matsuda M, Matsuoka K, et al. Quasispecies analyses of the HIV-1 near-full-length genome with illumina MiSeq. Front Microbiol. 2015;6:1258. doi:10.3389/fmicb.2015.0125826617593
   PubMed Web of Science ®Google Scholar
• Thys K, Verhasselt P, Reumers J, Verbist M, Maes B, Aerssens J. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. J Virol Methods. 2015;221:29–39. doi:10.1016/j.jviromet.2015.04.02225917877
   PubMed Web of Science ®Google Scholar
• Verbist B, Clement L, Reumers J, et al. ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clustering. BMC Bioinf. 2015;16(1). doi:10.1186/s12859-015-0458-7
   Web of Science ®Google Scholar
• Ram D, Leshkowitz D, Gonzalez D, Forer R, Levy I, Chowers M. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J Virol Methods. 2015;212(212):12–16. doi:10.1016/j.jviromet.2014.11.00325445792
   PubMed Web of Science ®Google Scholar
• UNDP-EUE. Preliminary examination of major factors affecting subsistence economy of South Omo Zone and Konso special wereda in South-western Ethiopia” UNDP-EUE Report, May 1996. 1996.
   Google Scholar
• CSA. Ethiopia-population and housing census of 2007. Central statistics agency -Ministry of Finance and Economic Development 2007; ETH_PHC-v01_M, Addis Ababa, Ethiopia; 2007.
   Google Scholar
• Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–166. doi:10.1016/S1473-3099(09)70328-720185094
   PubMed Web of Science ®Google Scholar
• QIAGEN. QIAamp^® viral RNA mini handbook for purification of viral RNA from plasma, serum, cell-free body fluids, and cell-culture supernatants. 2014.
   Google Scholar
• Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79:5112–5120. doi:10.1128/AEM.01043-1323793624
   PubMed Web of Science ®Google Scholar
• Liu T, Shafer R. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–1618. doi:10.1086/50391416652319
   PubMed Web of Science ®Google Scholar
• Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30(12):2725–2729. doi:10.1093/molbev/mst19724132122
   PubMed Web of Science ®Google Scholar
• Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298–303. doi:10.1093/nar/gkg10012520007
   PubMed Web of Science ®Google Scholar
• Barennes H, Guillet S, Limsreng S, et al. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia. PLoS One. 2014;9(8):e105736. doi:10.1371/journal.pone.010573625166019
   PubMed Web of Science ®Google Scholar
• Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–425.3447015
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Gunthard HF, et al. 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132–133.
   PubMedGoogle Scholar
• Abebe A, Kuiken C, Goudsmit J, et al. HIV type 1 subtype C in Addis Ababa, Ethiopia. AIDS Res Hum Retroviruses. 1997;13:1071–1075. doi:10.1089/aid.1997.13.10719264295
   PubMed Web of Science ®Google Scholar
• Amogne W, Bontell I, Grossmann S, et al. Phylogenetic analysis of Ethiopian HIV-1 subtype C near full-length genomes reveals high intrasubtype diversity and a strong geographical cluster. AIDS Res Hum Retroviruses. 2016;32(5):471–474. doi:10.1089/aid.2015.038026881451
   PubMed Web of Science ®Google Scholar
• Mulu A, Lange T, Liebert U, Maier M. Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis. 2014;1(158):1–9.
   Google Scholar
• Tully D, Wood C. Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia. AIDS. 2010;24(10):1577–1582. doi:10.1097/QAD.0b013e32833999e120539092
   PubMed Web of Science ®Google Scholar
• Abar A, Jlizi A, Darar H, et al. Human immunodeficiency virus type 1 in Djibouti. Arch Inst Pasteur Tunis. 2012;89(1):33–37.24834659
   PubMedGoogle Scholar
• Etta EM, Mavhandu L, Manhaeve C, et al. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa. AIDS Res Ther. 2017;14(1):36. doi:10.1186/s12981-017-0161-z28750647
   PubMed Web of Science ®Google Scholar
• Stadeli K, Richman D. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115–123. doi:10.3851/IMP243723052978
   PubMed Web of Science ®Google Scholar
• Ndahimana J, Riedel D, Mwumvaneza M, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Health. 2016;21(7):928–935. doi:10.1111/tmi.1271727125473
   PubMed Web of Science ®Google Scholar
• de Mulder M, Yebra G, Navas A, de Jose M, Gurbindo M, Gonzalez-Tome M. High drug resistance prevalence among verticallyHIV-infected patients transferred from pediatric care to adult units in Spain. PLoS One. 2012;7(12):e52155. doi:10.1371/journal.pone.005215523284913
   PubMed Web of Science ®Google Scholar
• Karadea S, Chaturbhuja D, Senb S, et al. HIV drug resistance following a decade of the free antiretroviral therapy programme in India: a review. Int J Infect Dis. 2018;66:33–41. doi:10.1016/j.ijid.2017.10.02029128646
   PubMed Web of Science ®Google Scholar
• Rhee SY, Jordan MR, Raizes E, et al. HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing. PLoS One. 2015;10(12):e0145772. doi:10.1371/journal.pone.014577226717411
   PubMed Web of Science ®Google Scholar
• Sinha R, Shekhar H, Ahmed N, et al. Prevalence of HIV drug resistance mutation in the Northern Indian population after failure of the first line antiretroviral therapy. Curr HIV Res. 2012;10(6):532–538.22716105
   PubMed Web of Science ®Google Scholar
• Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–1669. doi:10.1093/cid/cis25422474222
   PubMed Web of Science ®Google Scholar
• Ibe S, Sugiura W. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol. 2011;6(3):295–315. doi:10.2217/fmb.11.721449841
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh T, Devi KR, Singh L. Prevalence of drug resistance associated mutations among the anti retroviral therapy exposed HIV-1 infected individuals in Manipur, Northeast India. Curr HIV Res. 2016;14(4):360–370. doi:10.2174/1570162X1466616040113142627033350
   PubMed Web of Science ®Google Scholar
• Metznera K, Raucha P, Braunc P, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol. 2011;50:156–161. doi:10.1016/j.jcv.2010.10.00121056001
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Quinn JB, Benoit SL. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10(9):975–981. doi:10.1097/00002030-199610090-000078853730
   PubMed Web of Science ®Google Scholar
• Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246(4934):1155–1158. doi:10.1126/science.24799832479983
   PubMed Web of Science ®Google Scholar
• Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992;89(5):1934–1938. doi:10.1073/pnas.89.5.19341371886
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.. J Virol. 1996;70(9):5930–5934. doi:10.1128/jvi.70.9.5930-5934.19968709214
   PubMed Web of Science ®Google Scholar
• Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.. J Infect Dis. 2003;188(7):992–1000. doi:10.1086/37828114513419
   PubMed Web of Science ®Google Scholar
• Bacheler L, Anton E, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44(9):2475–2484. doi:10.1128/AAC.44.9.2475-2484.200010952598
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu W, Koh Y, et al. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007;51(2):429–437. doi:10.1128/AAC.01032-0617116677
   PubMed Web of Science ®Google Scholar
• Melikian G, Rhee S, Taylor J, et al. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012;56(5):2305–2313. doi:10.1128/AAC.05487-1122330916
   PubMed Web of Science ®Google Scholar
• Margot N, Johnson A, Miller M, Callebaut C. Characterization of HIV-1 resistance to tenofovir alafenamide in vitro. Antimicrob Agents Chemother. 2015;59(10):5917–5924. doi:10.1128/AAC.01151-1526149983
   PubMed Web of Science ®Google Scholar
• Mascolini M, Richman D, Larder B, Mellors J, Boucher CA. Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations. Antivir Ther. 2008;13:319–334.18505183
   PubMed Web of Science ®Google Scholar
• Hassan AS, Nabwera HM, Mwaringa SM, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther. 2014;11(1):9. doi:10.1186/1742-6405-11-924456757
   PubMed Web of Science ®Google Scholar
• Goldman JD, Cantrell RA, Mulenga LB. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24(8):1031–1035. doi:10.1089/aid.2008.003518724803
   PubMed Web of Science ®Google Scholar
• Assoumou L, Descamps D, Yerly S. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.. J Antimicrob Chemother. 2013;66(6):1400–1405. doi:10.1093/jac/dkt033
   Web of Science ®Google Scholar
• Boulle C, Kouanfack C, Laborde-Balen G. Prediction of HIV drug resistance based on virologic, immunologic, clinical, and /or adherence criteria in the stratall ANRS 12110/ESTHER trial in Cameroon. Clin Infect Dis. 2013;57(4):604–607. doi:10.1093/cid/cit32323667264
   PubMed Web of Science ®Google Scholar
• Rossouw TM, Nieuwoudt M, Manasa J, et al. HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa. HIV Med. 2017;18(2):104–114. doi:10.1111/hiv.1240027353262
   PubMed Web of Science ®Google Scholar